{"filing":{"accession_number":"0001437749-26-024041","cik":"0001645469","ticker":"MNPR","company_name":"Monopar Therapeutics","form":"8-K","filing_date":"2026-07-22","report_date":null,"primary_document":"mnpr20260721_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774926024041/mnpr20260721_8k.htm"},"events":[{"id":19345,"run_id":17406,"accession_number":"0001437749-26-024041","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Monopar announced initiation of a rolling New Drug Application submission for ALXN1840 to the FDA for Wilson disease treatment. This is a material regulatory and operational milestone for a clinical-stage biopharmaceutical company—the transition from clinical development to formal FDA review represents a significant advancement in the product development pathway. While not a specific named event type, this clearly falls within operational/strategic business milestones that would affect investor assessment of the company's progress and prospects.","company_name":"Monopar Therapeutics","ticker":"MNPR","filing_date":"2026-07-22","form":"8-K","submitted_at":null,"items":[{"id":18408,"accession_number":"0001437749-26-024041","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Monopar announced initiation of a rolling New Drug Application submission for ALXN1840 to the FDA for Wilson disease treatment. This is a material regulatory and operational milestone for a clinical-stage biopharmaceutical company—the transition from clinical development to formal FDA review represents a significant advancement in the product development pathway. While not a specific named event type, this clearly falls within operational/strategic business milestones that would affect investor assessment of the company's progress and prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-22T12:00:37.839925+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":18408,"accession_number":"0001437749-26-024041","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Monopar announced initiation of a rolling New Drug Application submission for ALXN1840 to the FDA for Wilson disease treatment. This is a material regulatory and operational milestone for a clinical-stage biopharmaceutical company—the transition from clinical development to formal FDA review represents a significant advancement in the product development pathway. While not a specific named event type, this clearly falls within operational/strategic business milestones that would affect investor assessment of the company's progress and prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-22T12:00:37.839925+00:00","company_name":"Monopar Therapeutics","ticker":"MNPR","filing_date":"2026-07-22"}]}